Don’t start uric-acid–lowering drugs just because a check-up found high uric acid and you have never had pain
In plain terms
For people whose uric acid is over the limit but who have never had a gout attack or tophi, the American College of Rheumatology advises not starting uric-acid–lowering drugs yet. Treat 24 people for 3 full years and you prevent only one gout attack. Hoping it protects the kidneys also fails: kidney patients on the drug still lose kidney function as fast as those on placebo. Treat only after a real attack.
Cost
No money, and you also save long-term drug costs and money for regular follow-up labs, and you skip one unnecessary drug risk.
Benefit
The American College of Rheumatology 2020 gout guideline covers asymptomatic hyperuricemia: blood uric acid >6.8 mg/dL, with no prior gout attack and no subcutaneous tophi. The guideline conditionally recommends that these people not start any uric-acid–lowering drug. Drugs include allopurinol, febuxostat, and probenecid. Evidence certainty is rated “high.” A table footnote states that “by attributable risk, 24 patients must be treated for 3 years to prevent one gout attack.” The CKD-FIX randomized controlled trial enrolled 363 people with stage 3 or 4 chronic kidney disease, no gout history, but risk of worsening. One group took 100–300 mg allopurinol daily; one took placebo. The trial ran 104 weeks. eGFR is a kidney-function marker in mL/min/1.73 m². One group changed −3.33 per year (95% CI −4.11 to −2.55). The other −3.23 (−3.98 to −2.47). The difference was −0.10 (−1.18 to 0.97), P=0.85 — kidney function fell at the same speed. Serious adverse events 46% versus 44%. The PERL randomized controlled trial enrolled 530 people with type 1 diabetes and early-to-mid diabetic kidney disease; they took allopurinol for 3 years, then stopped for 2 months to wash out the effect. Allopurinol did lower blood uric acid from 6.1 to 3.9 mg/dL. After washout, the two groups’ GFR differed by only 0.001 mL/min/1.73 m². The credible range for that difference is 95% CI −1.9 to 1.9, P=0.99. Urinary albumin was 40% higher on allopurinol (0 to 80). It looks worthwhile because the intuition “the marker is high so take a drug to push it down” is smooth.
Applicability and notes
What to reject is “start lifelong uric-acid–lowering drugs when you have never had an attack,” not “high uric acid does not matter.” The same guideline lists exceptions. The cases below may warrant starting. First: a first attack plus stage 3 or higher chronic kidney disease. Second: blood uric acid >9 mg/dL (about 535 µmol/L). Third: a history of urinary stones. People with tophi, bone erosion on imaging, or 2 or more attacks a year get a strong recommendation to take drugs; those with more than one attack but under 2 a year get a conditional recommendation. Details: Section 16, Item 9 (once gout is confirmed, take uric-acid–lowering drugs long term). About 7.4% of Han Chinese carry the HLA-B*5801 genotype versus 0.7% of White people. Carriers on allopurinol are more likely to get life-threatening severe drug rash; Asian risk of hypersensitivity syndrome is 3 times that of White people. This is a drug you can skip for now; there is no need to take that extra risk. Before starting, test for the genotype — Section 16, Item 9. The two kidney trials were in chronic kidney disease and type 1 diabetes; they cannot be stretched to “high uric acid is wholly harmless to kidneys.” They only reject “lowering uric acid with drugs protects the kidneys.”
Original sources
FitzGerald JD, Dalbeth N, Mikuls T, et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6), 744-760(表 1 及其脚注). https://doi.org/10.1002/acr.24180;Badve SV, Pascoe EM, Tiku A, et al. (2020). Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 382(26), 2504-2513. https://doi.org/10.1056/NEJMoa1915833;Doria A, Galecki AT, Spino C, et al. (2020). Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 382(26), 2493-2503. https://doi.org/10.1056/NEJMoa1916624
Original location:6.19 · View source file